SCHEMBL18034847

SCHEMBL18034847

FC(F)(F)Oc1ccc(Nc2ccc3cccc(CI)c3n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.52
KCNH2 Q12809 2/20 0.43
SCN5A Q14524 2/20 0.43
SCN9A Q15858 2/20 0.43
ABL1 P00519 8/20 0.41
BCR P11274 7/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
RAB9A P51151 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
HTT P42858 2/20 0.40
BRAF P15056 1/20 0.39
EPHX2 P34913 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPK1 P28482 1/20 0.38
PLK1 P53350 1/20 0.38
CTSC P53634 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1706290 0.83 DHFR (0.55) DHFRKCNH2SCN5ASCN9AABL1
SCHEMBL19380740 0.83 DHFR (0.55) DHFRKCNH2SCN5ASCN9AABL1
SCHEMBL16388751 0.82 DHFR (0.54) DHFRKCNH2SCN5ASCN9AABL1
SCHEMBL1705361 0.82 DHFR (0.54) DHFRKCNH2SCN5ASCN9AABL1
Obefazimod SCHEMBL1705888 0.82 DHFR (0.54) DHFRKCNH2SCN5ASCN9AABL1
SCHEMBL1702468 0.82 DHFR (0.58) DHFRKCNH2SCN5ASCN9AABL1
Obefazimod SCHEMBL29157012 0.81 DHFR (0.53) DHFRKCNH2SCN5ASCN9AABL1
Obefazimod SCHEMBL30729382 0.81 DHFR (0.53) DHFRKCNH2SCN5ASCN9AABL1
SCHEMBL1702461 0.80 DHFR (0.53) DHFRKCNH2SCN5ASCN9AABL1
SCHEMBL25941674 0.79 DHFR (0.54) DHFRKCNH2SCN5ASCN9AABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3059591-A1 Methods for screening compounds for treating or preventing a viral infection or a virus-related condition ABIVAX (FR) 2016-08-24 EP disclosed